What are the recommended coronary intervention strategies for adult patients with symptomatic coronary artery disease?

Recommended Coronary Intervention Strategies for Symptomatic Coronary Artery Disease

For patients with symptomatic chronic coronary syndrome (CCS), revascularization with either PCI or CABG is recommended in addition to guideline-directed medical therapy, with the specific modality determined by coronary anatomy, left ventricular function, and anatomic complexity using validated risk scores. 1

Initial Assessment and Risk Stratification

Before determining revascularization strategy, assess the following critical parameters:

• Calculate SYNTAX score to quantify anatomical complexity of multivessel disease 1
• Calculate STS score to estimate surgical morbidity and 30-day mortality for CABG 1
• Measure left ventricular ejection fraction (LVEF) as this fundamentally changes treatment algorithms 1
• Use intracoronary pressure measurement (FFR or iFR) to guide lesion selection in multivessel disease 1

Revascularization Indications Based on Anatomy and LVEF

For Patients with LVEF >35%

Left Main Disease:

• CABG is the preferred revascularization mode over PCI for left main stenosis, given lower risk of spontaneous MI and repeat revascularization 1
• PCI is an acceptable alternative only for low-complexity left main disease (SYNTAX score ≤22) where equivalent completeness of revascularization can be achieved 1
• Both CABG and PCI improve survival compared to medical therapy alone 1

Three-Vessel Disease:

• Myocardial revascularization is recommended to improve long-term survival and reduce cardiovascular mortality and spontaneous MI 1
• CABG may be reasonable to improve survival based on contemporary trial evidence 1
• Survival benefit with PCI in three-vessel disease remains uncertain 1

Single- or Two-Vessel Disease with Proximal LAD:

• Revascularization is recommended to reduce long-term cardiovascular mortality and spontaneous MI risk 1

For Patients with LVEF ≤35%

• CABG is recommended over medical therapy alone in surgically eligible patients with multivessel CAD to improve long-term survival 1
• PCI may be considered in selected patients at high surgical risk or inoperable, though this is a weaker recommendation 1
• Treatment decisions require Heart Team evaluation considering coronary anatomy, correlation between CAD and LV dysfunction, comorbidities, and life expectancy 1

Symptom-Driven Revascularization

For patients with persistent angina despite guideline-directed medical therapy, revascularization of functionally significant obstructive CAD is recommended to improve symptoms. 1

This indication applies regardless of anatomic complexity, though the choice between PCI and CABG still depends on anatomic factors 1.

Technical Optimization Strategies

Intracoronary Imaging

Use IVUS or OCT guidance when performing PCI on anatomically complex lesions, particularly:

• Left main stem 1
• True bifurcations 1
• Long lesions 1

Physiologic Assessment

• FFR or iFR measurement is recommended to guide lesion selection in multivessel disease 1
• Consider post-procedural FFR/iFR to identify patients at high risk of persistent angina and subsequent events 1

Access Site Selection

Radial artery access is recommended for both acute coronary syndromes and stable ischemic heart disease to reduce bleeding and vascular complications compared to femoral approach 1

Surgical Conduit Selection

When performing CABG, use radial artery as the conduit for the second most important target vessel (after LAD) rather than saphenous vein, as this provides superior patency, reduced adverse cardiac events, and improved survival 1.

Multidisciplinary Decision-Making

When the optimal treatment strategy is unclear, a Heart Team approach is recommended with patient-centered decisions incorporating patient preferences and shared decision-making 1. This is particularly critical for:

• Complex multivessel disease 1
• Left main disease 1
• Reduced LVEF scenarios 1

Common Pitfalls to Avoid

• Do not rely on angiographic appearance alone in multivessel disease—use FFR/iFR to identify functionally significant lesions 1
• Do not assume PCI and CABG are equivalent for complex multivessel disease or left main with high SYNTAX scores—CABG remains superior in these anatomies 1
• Do not overlook the importance of completeness of revascularization—this significantly impacts outcomes, particularly in reduced LVEF patients 1
• Do not perform revascularization without optimizing medical therapy first unless dealing with high-risk anatomy or refractory symptoms 2, 3

Antiplatelet Therapy Duration

After PCI in stable ischemic heart disease, a short duration of dual antiplatelet therapy (1-3 months) is reasonable to reduce bleeding risk, with transition to P2Y12 inhibitor monotherapy after careful consideration of ischemia versus bleeding risk 1.